ストックスクリーナーアプリを入手
1,251.61
3.55%
42.87
アフターアワーズ：
1253.70
2.09
+0.17%
Lilly Eli Co (LLY) 最新ニュース
Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsight - GlobeNewswire Inc.
Viking Therapeutics Starts Phase III Development of Obesity Pill - Zacks Investment Research
Can Nektar's Pipeline Progress Create Long-Term Value Amid Rivalry? - Zacks Investment Research
Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today - Zacks Investment Research
5 Stocks to Start With if You Only Have $1,000 - The Motley Fool
Is First Trust NASDAQ Pharmaceuticals ETF (FTXH) a Strong ETF Right Now? - Zacks Investment Research
Roche Expands Obesity Pipeline With Rona's RNAi Candidate - Zacks Investment Research
Stock Market Midday, Oct. 14: Hot Inflation Weighs on Markets, CoreWeave Plummets 15% - The Motley Fool
Eli Lilly and Co Stock (LLY) Opened Up by 3.70% on Oct 14: Key Drivers Unveiled - TradingKey
Eli Lilly schedules October 29 earnings as Eli Lilly stock sits 4.73 percent below its high - ad-hoc-news.de
4 High-Risk Stocks Built for Big Returns - The Motley Fool
A Look at Eli Lilly and Co (LLY) After 1.4% Decline -- GF Value $1575.10 vs Price $1166.51 - GuruFocus
Bristol Myers Squibb vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Here's Why Eli Lilly (LLY) Fell More Than Broader Market - Zacks Investment Research
Eli Lilly & Co. stock outperforms competitors despite losses on the day - MarketWatch
3 Dividend Growth Stocks That Have Doubled Their Payouts in 5 Years - The Motley Fool
BMO Capital Sticks to Its Buy Rating for Eli Lilly & Co (LLY) - The Globe and Mail
RBC Capital Sticks to Their Buy Rating for Eli Lilly & Co (LLY) - The Globe and Mail
RBC Capital Sticks to Their Buy Rating for Eli Lilly & Co (LLY) - The Globe and Mail
AbbVie, Eli Lilly among mega-cap healthcare stocks with A+ profitability grades (XLV:NYSEARCA) - Seeking Alpha
AbbVie, Eli Lilly among mega-cap healthcare stocks with A+ profitability grades - TradingView
Should Invesco Dividend Achievers ETF (PFM) Be on Your Investing Radar? - Zacks Investment Research
Eli Lilly Expects Up to $87 Billion in 2026 Revenue. Here's Why the Stock Still Looks Undervalued. - The Motley Fool
Lilly Begins On $6.5B Houston Manufacturing Facility : CEG - Construction Equipment Guide
AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
Lilly seeks to provide $19.3M to Lebanon for expanded hazmat services - Inside INdiana Business
Novo Down 11% in a Month: How Should Investors Approach the Stock Now? - Zacks Investment Research
4 Healthcare Stocks Worth Owning for the Next Decade - The Motley Fool
Pfizer Moves Past 50-Day SMA: Time to Buy, Hold or Exit the Stock? - Zacks Investment Research
Oppenheimer Thinks Viking Therapeutics Stock Can Soar to $120. Here's the Math Behind the Ultra-Bullish Call. - The Motley Fool
Eli Lilly presented new trial data. Eli Lilly stock gains 1.09 percent - ad-hoc-news.de
Eli Lilly Stock Has Pulled Back 8%. History Says This Is What Happens Next. - The Motley Fool
Eli Lilly says combining Taltz and Zepbound works better than Taltz alone in psoriasis study - MedWatch
Which iShares Healthcare ETF Is the Better Buy: Biotech-Focused IBB or Broad IYH? - The Motley Fool
Which Healthcare ETF Is the Better Buy: Simplify’s Active PINK or VanEck’s Pharma-Focused PPH? - The Motley Fool
Eli Lilly Sued Over Alleged Digestive Complications From GLP-1 Medication - InkFreeNews.com
As GLP-1 Drugs Change How People Eat, Drugmakers Collect and Snack Makers Feel the Squeeze - The Motley Fool
Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock? - The Motley Fool
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Legend Biotech (LEGN) and Bristol-Myers Squibb (BMY) - The Globe and Mail
Eli Lilly-Backed Biotech TRex Dips 3.6% After $116.7 Million IPO - Bloomberg.com
Eli Lilly Lobs 4 Suits Alleging Illegal Weight Loss Drug Sales - Law360
Eli Lilly Says Weight Clinic 'Mocks' FDA With Illegal Drugs - Law360
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock - Zacks Investment Research
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock - Yahoo Finance
3 Top-Ranked Healthcare Mutual Funds for a Defensive Portfolio - Zacks Investment Research
Why Investors Need to Take Advantage of These 2 Medical Stocks Now - Zacks Investment Research
Eli Lilly & Co (LLY) Receives a Buy from Cantor Fitzgerald - The Globe and Mail
UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument. - The Motley Fool
Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Eli Lilly sued over stomach problems patient ties to Mounjaro and Trulicity - Inside INdiana Business
0.25%
2.38%
大文字化:
|
ボリューム (24 時間):